ReviewMicrobiologyOpen2026
Intrinsic Disorder as a New Frontier in Antimicrobial Resistance and Bacterial Fitness.
Review in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Intrinsically disordered proteins (IDPs) are biological macromolecules lacking a well-defined structure under normal physiological conditions. These proteins can be essential for both eukaryotic and prokaryotic cells, yet bacterial IDPs are significantly understudied. In this review, we highlight the functional importance of intrinsic disorder across a range of microbial phenomena, including effector secretion, desiccation tolerance, and the bacterial stress response. Given the emergence of structural disorder in key mechanisms of bacterial fitness, we propose bacterial intrinsic disorder as a novel linkage to antimicrobial resistance (AMR). We highlight areas of research where further study of bacterial IDPs could provide new insights into microbial evolution. Functional disorder introduces a new paradigm to the challenge of AMR, identifying novel targets for antimicrobial therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.